Colorectal Cancer clinical trials in Kansas

12 actively recruiting colorectal cancer trials at 11 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT07018869

Sites in Kansas:

Central Care Cancer Center - Garden City — Garden City, Kansas
Central Care Cancer Center - Great Bend — Great Bend, Kansas
Mercy Hospital Pittsburg — Pittsburg, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…

Sponsor: Rapamycin Holdings Inc.

NCT ID: NCT06950385

Sites in Kansas:

University of Kansas Medical Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.

NCT ID: NCT05592626

Sites in Kansas:

The University of Kansas Cancer Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric canc…

Sponsor: Anwaar Saeed

NCT ID: NCT03539822

Sites in Kansas:

University of Kansas Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study

This trial evaluates how inhalational anesthesia (drawn in through the lungs) and total intravenous anesthesia (TIVA) (through a needle in a vein in the arm) change the body's ability to recover from surgery or whether they impact the immu…

Sponsor: University of Kansas Medical Center

NCT ID: NCT06017141

Sites in Kansas:

University of Kansas Cancer Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other pl…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05803382

Sites in Kansas:

University of Kansas Clinical Research Center — Fairway, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting NIH

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has co…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06102902

Sites in Kansas:

University of Kansas Clinical Research Center — Fairway, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting NIH

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first s…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06696768

Sites in Kansas:

University of Kansas Clinical Research Center — Fairway, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy…

Sponsor: BeiGene

NCT ID: NCT06585488

Sites in Kansas:

University of Kansas Medical Center Research Institute — Kansas City, Kansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Kansas:

Central Care Cancer Center - Garden City — Garden City, Kansas
Central Care Cancer Center - Great Bend — Great Bend, Kansas
Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
Mercy Hospital Pittsburg — Pittsburg, Kansas
Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas

View on ClinicalTrials.gov →

Recruiting Industry

Shield Post-Approval Study Protocol

The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individ…

Sponsor: Guardant Health, Inc.

NCT ID: NCT06880055

Sites in Kansas:

Hutchinson Clinic — Hutchinson, Kansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

Exosomes in Rectal Cancer

The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemora…

Sponsor: University of Kansas Medical Center

NCT ID: NCT03874559

Sites in Kansas:

University of Kansas Medical Center/ Cancer Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20